chf5633
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02452476)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Presenilin 1INHIBITOR
PSEN1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- chf5633
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02452476 | Phase 2 | Jan 1, 2016 | Chiesi, Parexel, Tufts University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 1 | 1 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
| Tufts University | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1